Drug news
AEZS-108 to commence Phase III trial for Endometrial Cancer
The FDA has approved an upcoming Phase III registration trial in Endometrial Cancer for AEZS-108 from Aeterna Zentaris Inc. This will be an open-label, randomized, multicenter Phase III trial conducted in North America and Europe, comparing AEZS-108 with doxorubicin as second line therapy for locally-advanced, recurrent or metastatic Endometrial Cancer. The trial will involve approximately 500 patients and the primary efficacy endpoint is improvement in median Overall Survival.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.